Innovative Trial Model Science 37's FDA-inspected Direct-to-Patient Site model demonstrates a strong commitment to decentralized clinical trials, enabling faster enrollment and higher retention, which can be attractive to clients seeking efficient trial execution.

Industry Recognition The company's recent awards, including the Global Company of the Year and site innovation accolades, position it as a leader in the decentralized clinical trial space, making it a compelling partner for organizations aiming to enhance trial accessibility.

Growing Market Presence With a revenue range of 50 to 100 million dollars and receive diverse industry awards, Science 37 is expanding its influence, presenting opportunities to collaborate with a recognized innovator in patient-centric research solutions.

Technology Enablement Utilizing a modern tech stack including AWS Lambda, Node.js, and cloud-based data management, Science 37 offers scalable and efficient digital platforms, providing potential for partners seeking advanced technological integration in clinical trials.

Strategic Partnerships Recent collaborations such as with the CGD Association of America highlight Science 37’s ability to engage with specialized health organizations, opening avenues for customized trial solutions in niche therapeutic areas.